Promising New Compound Protects Neurons and Vision in Mice with Glaucoma
London, April 19, 2016
Early tests of a novel compound in mice with glaucoma should come as welcome news to millions of people around the world now suffering with this leading cause of vision loss. Researchers reporting in the journal Heliyon have shown that a compound they’ve developed might help to prevent the nerve damage that leads people with glaucoma to lose their sight.
The only treatments available for glaucoma today include surgery or drugs used to reduce pressure in the eye. However, many patients continue to experience gradual vision loss despite those treatments.
“Our newly developed small compounds prevented the progression of glaucoma in three different mouse models,” said Hanako Ikeda of Kyoto University in Japan.
The findings in mice suggest that these compounds, dubbed KUSs [Kyoto University Substances] “might slow down disease progression and prolong normal or near-normal vision [in people with glaucoma]; ideally, KUSs might prevent the eventual loss of eyesight,” she added.
Ikeda and her colleagues have worked for years to understand what causes the death of neural cells in the eye. They previously uncovered strong evidence for a role of an enzyme called VCP (valosin-containing protein). This enzyme acts as an ATPase, breaking down ATP molecules that serve as the cellular currency for energy.
“We thus assumed that specific inhibitors of the VCP ATPase activity would prevent neuronal cell death and the disease symptoms as well,” Ikeda said.
She and her colleagues went in search of a compound with the right activity. The search led them to KUSs. Earlier studies in cells suggested that these KUSs could help to maintain ATP levels, reduce cellular stress, and protect neurons.
Now, they show that KUSs delivered orally or through injections also protect neurons of the retina in mice with glaucoma. Mice with glaucoma treated with KUSs showed less thinning of the retinal nerve fiber layer than did those treated with a control. KUSs also helped to preserve visual functions, apparently by maintaining ATP levels.
“In cells that are dying, an almost universal phenomenon is that ATP levels gradually decrease,” Ikeda said. “KUSs maintain cellular ATP levels by inhibiting the ATPase activity of VCP. In other words, inhibiting the ATPase activity of VCP frees up ATP for other essential cellular processes and consequently prevents or retards cell death.”
The researchers say their compounds could offer neural protection in glaucoma and perhaps other neurodegenerative diseases as well. Their next step is to study the mechanisms of cell protection in the mice in greater detail. Plans are underway for a phase I/II clinical trial to test the safety and efficacy of KUSs in people with an acute ocular disease. They say it will take at least another three to five years before a trial of KUSs in people with glaucoma could begin.
“Neuroprotective effects of VCP modulators in mouse models of glaucoma” by Nakano et al. (doi: 10.1016/j.heliyon.2016.e00096). The article appears in Heliyon (April 2016), published by Elsevier.
This paper is strictly under embargo until 11:00 AM BST (British Summer Time) on Tuesday April 19, 2016.
In online coverage of this paper, please mention the journal Heliyon and link to the paper at http://www.heliyon.com/article/e00096/
Representative retinal flatmount images of the 12 month-old GLAST (+/-) mice, a glaucoma model, administered KUS 121 or PBS as a control (vehicle). Each dot represents a spared retinal ganglion cell. Rays converging at the center (the optic nerve head) represent spared nerve fibers. The retina treated with KUS121 has more retinal ganglion cells and nerve fibers, as compared with that of the non-treated control mouse. Credit: Noriko Nakano and Hanako Ikeda
Heliyon is an open access journal from Elsevier publishing quality research papers across all disciplines. Our editorial team is committed to improving the researcher experience by providing excellent editorial service, fast publication, and high visibility for all papers. Every article is immediately and permanently available for readers to read, download, and share on both Heliyon.com and ScienceDirect. The article publishing charge (APC) for papers accepted by Heliyon is $1,250 (plus VAT and local taxes where applicable).
About Kyoto University
Kyoto University is one of Japan and Asia's premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information please contact firstname.lastname@example.org or see http://www.kyoto-u.ac.jp/en
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Mary Beth O’Leary
Heliyon Marketing & Publicity Manager
+44 2074 244 343
+44 7881 330 150
David Hajime Kornhauser
Director, Global Communications
+81 75 753 5727